# Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo

> **NCT01419977** · PHASE2 · COMPLETED · sponsor: **Duke University** · enrollment: 34 (actual)

## Conditions studied

- Sickle Cell Disease
- Vaso-occlusive Crisis

## Interventions

- **DRUG:** Placebo
- **DRUG:** Dalteparin

## Key facts

- **NCT ID:** NCT01419977
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2013-07
- **Final completion:** 2014-07
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2015-02-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01419977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01419977, "Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT01419977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*